TheraRadar
← Back
Data updated: May 24, 2026

AZURITY

Specialty

AZURITY is a specialty pharmaceutical company focused on Cardiovascular, Oncology, Neurology. Key products include FIRVANQ KIT.

1954
Since
59
Drugs
-
Trials
7
New Drugs (2yr)
Modality:
43 Small Molecules

Recent FDA Approvals

New drug approvals (NDA/BLA) in the last 2 years. Shows novel drugs only, excluding generics and label supplements.

JAVADIN NDA
2025-10-23
clonidine hydrochloride
Hypertension
FERABRIGHT NDA
2025-10-16
ferumoxytol
Malignant Neoplasm
ARYNTA NDA
2025-06-16
lisdexamfetamine dimesylate
Attention Deficit Hyperactivity Disorder
WIDAPLIK NDA
2025-06-05
amlodipine besylate
1 INDICATIONS AND USAGE Widaplik (telmisartan/amlodipine/indapamide) is indicated for the treatment of hypertension in adult patients, to lower blood pressure. Widaplik may be used as initial therapy in patients likely to need multiple drugs to achieve blood pressure goals. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including angiotensin II receptor blockers, dihydropyridine calcium channel blockers and thiazide-like diuretics. There are no controlled trials demonstrating risk reduction with Widaplik. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at h
XIFYRM NDA
2025-06-05
meloxicam
Pain
BRYNOVIN NDA
2025-01-16
sitagliptin hydrochloride
Type 2 Diabetes
DANZITEN NDA
2024-11-07
nilotinib tartrate
Chronic Myeloid Leukemia

Therapeutic Areas

Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.

Cardiovascular 40%
11 drugs
Oncology 26%
7 drugs
Neurology 15%
4 drugs Phase 1: 1
Metabolic 11%
3 drugs
Infectious Disease 7%
2 drugs

Pipeline Snapshot

Active clinical trials across all therapeutic areas. Data from ClinicalTrials.gov.

0
Phase 3
0
Phase 2
1
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • FIRVANQ KIT leads revenue
  • 5 key drugs tracked

Trial Catalysts

  • Cardiovascular pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling